AfroCAB

Afrocab Treatment Access Partnership (Afrocab) is an African network comprising HIV community leaders and advocates dedicated to expediting access to optimal HIV and co-morbidity treatments and prevention products. The organization primarily operates within sub-Saharan Africa, with its headquarters situated in Zambia and a network spanning across 19 countries. Established in 2011, Afrocab aims to facilitate dialogue on community treatment access among multinational and generic drug manufacturing companies, policymakers, UN agencies, civil society organizations, and other stakeholders involved in anti-HIV drugs and clinical research of new molecules and diagnostics.

Currently, Afrocab focuses on three key areas:

1. Global Advocacy: Advocating at the global level to ensure the highest quality and most cost-effective treatment and prevention of HIV in Africa.
2. Building Global and Regional Networks: Establishing networks and partnerships at both global and regional levels to enhance collaboration and support in achieving Afrocab's objectives.
3. Continental and Country Coordination: Promoting coordination efforts at both continental and country levels to create an ecosystem approach for addressing the complexities of HIV treatment and prevention delivery.

CHAI CAB (Community Advisory Board):
The establishment of the Community Advisory Board (CAB) aims to facilitate engagement with civil society groups to collaboratively develop product adoption and roll-out strategies, as well as enhance understanding and demand for new medicines. The CAB plays a crucial role in providing strategic direction and leadership to strengthen community engagement in project implementation. It also focuses on fostering demand generation and ensuring that the project aligns with and complements the activities of the global HIV treatment community.